RATIO THERAPEUTICS HAS SUCCESSFULLY DOSED THE FIRST COHORT IN ITS PHASE 1/2 STUDY EVALUATING A NOVEL FAP-TARGETED RADIOPHARMACEUTICAL IN PATIENTS WITH LATE-STAGE AGGRESSIVE SARCOMAS

Reuters · 21h ago

Please log in to view news